Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H21FN4O3.3H2O |
| Molecular Weight | 450.4607 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.[H][C@]12CN(C[C@@]1([H])NCCC2)C3=C(C#N)C4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O
InChI
InChIKey=OTPLAFVGCAMVAC-DEWAGMQLSA-N
InChI=1S/C21H21FN4O3.3H2O/c22-16-6-13-18(26(12-3-4-12)9-15(20(13)27)21(28)29)14(7-23)19(16)25-8-11-2-1-5-24-17(11)10-25;;;/h6,9,11-12,17,24H,1-5,8,10H2,(H,28,29);3*1H2/t11-,17+;;;/m0.../s1
Pradofloxacin (trade name Veraflox) is a 3rd generation enhanced spectrum veterinary antibiotic of the fluoroquinolone class. It was developed by Bayer HealthCare AG, Animal Health GmbH, and received approval from the European Commission in April 2011 for prescription-only use in veterinary medicine for the treatment of bacterial infections in dogs and cats. The primary mode of action of fluoroquinolones involves interaction with enzymes essential for major DNA functions such as replication, transcription, and recombination. The primary targets for Pradofloxacin are the bacterial DNA gyrase and topoisomerase IV enzymes. Reversible association between Pradofloxacin and DNA gyrase or DNA topoisomerase IV in the target bacteria results in inhibition of these enzymes and rapid death of the bacterial cell. The rapidity and extent of bacterial killing are directly proportional to the drug concentration.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antimicrobial drug susceptibility of Staphylococcus intermedius clinical isolates from canine pyoderma. | 2005 Feb |
|
| In vivo tolerance and kinetics of a novel ocular drug delivery device. | 2006 Nov 28 |
|
| Mutant prevention concentration of pradofloxacin against Porphyromonas gingivalis. | 2007 Mar 31 |
|
| Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. | 2007 Nov |
|
| Clinical efficacy and palatability of pradofloxacin 2.5% oral suspension for the treatment of bacterial lower urinary tract infections in cats. | 2007 Sep-Oct |
|
| Pharmacokinetics of pradofloxacin and doxycycline in serum, saliva, and tear fluid of cats after oral administration. | 2008 Apr |
|
| Efficacy of pradofloxacin in cats with feline upper respiratory tract disease due to Chlamydophila felis or Mycoplasma infections. | 2008 Jan-Feb |
|
| Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography. | 2008 May |
|
| Evaluation of pradofloxacin for the treatment of feline rhinitis. | 2008 Oct |
|
| Use of pradofloxacin to treat experimentally induced Mycoplasma hemofelis infection in cats. | 2009 Jan |
|
| Identification of Qnr and AAC(6')-1b-cr plasmid-mediated fluoroquinolone resistance determinants in multidrug-resistant Enterobacter spp. isolated from extraintestinal infections in companion animals. | 2010 Jul 14 |
|
| Molecular mechanisms of Bartonella henselae resistance to azithromycin, pradofloxacin and enrofloxacin. | 2010 Mar |
|
| Haemotropic mycoplasmas: what's their real significance in cats? | 2010 May |
|
| Fluoroquinolone resistance mechanisms in multidrug-resistant Escherichia coli isolated from extraintestinal infections in dogs. | 2010 Nov 20 |
|
| Evaluation of the clinical efficacy of pradofloxacin tablets for the treatment of canine pyoderma. | 2010 Sep-Oct |
Patents
Sample Use Guides
Administer 3.0 mg/kg bodyweight of pradofloxacin once daily.
Route of Administration:
Oral
The MIC of pradofloxacinc was determined by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) standards,6 within the concentration range 0.008–16 μg/mL. The MICs of enrofloxacin and ciprofloxacin were determined using commercial stripsd on Mueller–Hinton 2 agar inoculated with a bacterial suspension (density of 0.5 McFarland) and incubated for 24 h at 35°C. The reference strain S. aureus ATCC 25923 was used as a quality control for MIC determination with the commercial strips, according to the manufacturer’s instructions.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
67315146
Created by
admin on Sat Dec 16 19:50:45 GMT 2023 , Edited by admin on Sat Dec 16 19:50:45 GMT 2023
|
PRIMARY | |||
|
T9J58ERF3L
Created by
admin on Sat Dec 16 19:50:45 GMT 2023 , Edited by admin on Sat Dec 16 19:50:45 GMT 2023
|
PRIMARY | |||
|
866760-50-1
Created by
admin on Sat Dec 16 19:50:45 GMT 2023 , Edited by admin on Sat Dec 16 19:50:45 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
